Company Filing History:
Years Active: 2022
Title: Pei-Yun Hung: Innovator in Cancer Treatment
Pei-Yun Hung is a notable inventor based in Taipei, Taiwan. She has made significant contributions to the field of cancer treatment through her innovative research and development of histone deacetylases (HDACs) inhibitors. Her work focuses on creating compounds that can effectively target and treat various types of cancer.
Latest Patents
Pei-Yun Hung holds 1 patent related to histone deacetylases (HDACs) inhibitors. The patent discloses a structural formula for these inhibitors, which includes a benzene ring and a cyclohexane ring, both of which may be substituted. The HDACs inhibitors developed by Hung demonstrate cytotoxicity against various cancer cell lines. They are particularly useful for treating tumors associated with the deregulation of histone deacetylases activity. This includes applications for glioma, breast cancer, colon cancer, lung cancer, and several other malignancies.
Career Highlights
Pei-Yun Hung is affiliated with Annji Pharmaceutical Co., Ltd., where she continues her research and development efforts. Her work has positioned her as a key figure in the pharmaceutical industry, particularly in the area of cancer therapeutics.
Collaborations
Throughout her career, Pei-Yun Hung has collaborated with esteemed colleagues such as Ji-Wang Chern and Chao-Wu Yu. These collaborations have further enhanced her research capabilities and contributed to the advancement of cancer treatment options.
Conclusion
Pei-Yun Hung's innovative work in developing HDACs inhibitors represents a significant advancement in cancer treatment. Her contributions are vital in the ongoing fight against various forms of cancer, showcasing the importance of research and innovation in the medical field.